Fainting and drugs of ingredients of erenumab-aooe - a phase IV clinical study of FDA data


Summary:

Fainting is found among people who take drugs with ingredients of erenumab-aooe, especially for people who are female, 40-49 old , have been taking the drugs for < 1 month. This phase IV clinical study is created by eHealthMe based on reports of 38,925 people who have side effects when taking drugs with ingredients of erenumab-aooe from the FDA, and is updated regularly.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Aimovig.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.


On Nov, 30, 2022

38,925 people reported to have side effects when taking drugs with ingredients of erenumab-aooe.
Among them, 127 people (0.33%) have Fainting


What is Fainting?

Fainting (loss of consciousness and postural tone) is found to be associated with 3,579 drugs and 3,299 conditions by eHealthMe.

Number of reports submitted per year:

Could drugs with ingredients of erenumab-aooe cause Fainting?

Time on drugs with ingredients of erenumab-aooe when people have Fainting *:

  • < 1 month: 42.86 %
  • 1 - 6 months: 35.71 %
  • 6 - 12 months: 17.86 %
  • 1 - 2 years: 3.5700000000000003 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Fainting when taking drugs with ingredients of erenumab-aooe *:

  • female: 89.43 %
  • male: 10.57 %

Age of people who have Fainting when taking drugs with ingredients of erenumab-aooe *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 10 %
  • 20-29: 9 %
  • 30-39: 12 %
  • 40-49: 28 %
  • 50-59: 23 %
  • 60+: 18 %

Conditions people have *:

  1. Migraine (headache): 99 people, 77.95%
  2. Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 11 people, 8.66%
  3. Migraine Without Aura (headache without neurological problems): 4 people, 3.15%
  4. Nausea (feeling of having an urge to vomit): 3 people, 2.36%
  5. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 2.36%
  6. Headache (pain in head): 3 people, 2.36%
  7. High Blood Pressure: 3 people, 2.36%
  8. Generalized Anxiety Disorder (excessive, uncontrollable, unexplained and often irrational worry): 2 people, 1.57%
  9. Depression: 2 people, 1.57%
  10. Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 2 people, 1.57%

Other drugs people take *:

  1. Synthroid: 12 people, 9.45%
  2. Cortef: 9 people, 7.09%
  3. Topamax: 9 people, 7.09%
  4. Cambia: 9 people, 7.09%
  5. Elavil: 8 people, 6.30%
  6. Fish Oil: 8 people, 6.30%
  7. Toradol: 8 people, 6.30%
  8. Maxalt: 6 people, 4.72%
  9. Fiorinal: 5 people, 3.94%
  10. Zomig: 5 people, 3.94%

Other side effects people have besides Fainting *:

  1. Dizziness: 40 people, 31.50%
  2. Nausea (feeling of having an urge to vomit): 36 people, 28.35%
  3. Fatigue (feeling of tiredness): 34 people, 26.77%
  4. Migraine (headache): 30 people, 23.62%
  5. Headache (pain in head): 26 people, 20.47%
  6. Injection Site Pain: 23 people, 18.11%
  7. Chest Pain: 18 people, 14.17%
  8. Pain: 18 people, 14.17%
  9. Fall: 17 people, 13.39%
  10. Malaise (a feeling of general discomfort or uneasiness): 14 people, 11.02%

* Approximation only. Some reports may have incomplete information.


How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drugs with ingredients of erenumab-aooe, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on erenumab-aooe. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: